In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity at CYP-450

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 23, 2006, Pages 7972-7987

  Labrie, Philippe ^a,b   Maddaford, Shawn P ^c   Lacroix, Jacques ^a   Catalano, Concettina ^d   Lee, David K H ^d   Rakhit, Suman ^c   Gaudreault, René C ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c NeurAxon Inc MaRS Centre   (Canada)

^d NoAb BioDiscoveries Inc   (Canada)

Author keywords

Anthranilamide; Cytochrome P 450; Multidrug resistance; P glycoprotein modulators

Indexed keywords

6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLINE; AMIDE; AMINE; ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A4; GLYCOPROTEIN P; ISOQUINOLINE DERIVATIVE; N [2 [[[2 (6,7 METHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)BUTYL]AMINO] CARBONYL]PHENYL]QUINOLINE 3 CARBOXAMIDE; N [2 [[[2 (6,7 METHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]AMINO] CARBONYL]PHENYL]QUINOLINE 3 CARBOXAMIDE; N [2 [[[2 (6,7 METHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)HEXYL]AMINO] CARBONYL]PHENYL]QUINOLINE 3 CARBOXAMIDE; N [2 [[[2 (6,7 METHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)PENTYL]AMINO] CARBONYL]PHENYL]QUINOLINE 3 CARBOXAMIDE; N [2 [[[2 (6,7 METHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)PROPYL]AMINO] CARBONYL]PHENYL]QUINOLINE 3 CARBOXAMIDE; N [2 [[[[[2 (3,4 METHOXYPHENYL)ETHYL](METHYL)AMINO]BUTYL]AMINO]CARBONYL] PHENYL]QUINOLINE 3 CARBOXAMIDE; N [2 [[[[[2 (3,4 METHOXYPHENYL)ETHYL](METHYL)AMINO]ETHYL]AMINO]CARBONYL] PHENYL]QUINOLINE 3 CARBOXAMIDE; N [2 [[[[[2 (3,4 METHOXYPHENYL)ETHYL](METHYL)AMINO]HEXYL]AMINO]CARBONYL] PHENYL]QUINOLINE 3 CARBOXAMIDE; N [2 [[[[[2 (3,4 METHOXYPHENYL)ETHYL](METHYL)AMINO]PENTYL]AMINO]CARBONYL] PHENYL]QUINOLINE 3 CARBOXAMIDE; N [2 [[[[[2 (3,4 METHOXYPHENYL)ETHYL](METHYL)AMINO]PROPYL]AMINO]CARBONYL] PHENYL]QUINOLINE 3 CARBOXAMIDE; N METHYLHOMOVERATRYLAMINE; PACLITAXEL; TARIQUIDAR; UNCLASSIFIED DRUG;

ARTICLE; ATOM; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DISPOSITION; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; INTESTINE; TUMOR CELL;

ANTHRANILIC ACIDS; ATP-BINDING CASSETTE TRANSPORTERS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, MULTIPLE; HUMANS; P-GLYCOPROTEIN; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750198370     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.07.055     Document Type: Article

References (37)

1. Young R.C. Drug Resistance: The Clinical Problem. In: Ozols (Ed). Drug Resistance in Cancer Therapy (1989), Kluwer Academic, Boston 1-12
2. Glavinas H., Krajcsi P., Cserepes J., and Sarkadi B. Curr. Drug Deliv. 1 (2004) 27
3. Juliano R., and Ling V. Biochem. Biophys. Acta 455 (1976) 152
4. Fromm M.F. Int. J. Clin. Pharmacol. Ther. 38 (2000) 69
5. Benet L.Z., and Cummins C.L. Adv. Drug Deliv. Rev. 50 (2001) S3-S11
6. Tsuruo T., Iida H., Tsukagoshi S., and Sakurai Y. Cancer Res. 41 (1981) 1967
7. Slater L.M., Sweet P., Stupecky M., and Gupta S. J. Clin. Invest. 77 (1986) 1405
8. Tsuruo T., Iida H., Kitatani Y., Yokota K., Tsukagoshi S., and Sakurai Y. Cancer Res. 44 (1984) 4303
9. Pearce H.L., Safa A.R., Bach N.J., Winter M.A., Cirtain M.C., and Beck W.T. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 5128
10. Kajiti S., Dreslin J., Grissuti K., and Gros P. Biochemistry 33 (1994) 862
11. Tsuruo T., Iida H., Nojiri M., Tsukagoshi S., and Sakurai Y. Cancer Res. 43 (1983) 2905
12. Kawase M., and Motohashi N. Curr. Drug Targets 4 (2003) 31
13. Benson A.B., Trump D.L., Koeller J.M., Egorin M.I., Olman E.A., Witte R., and Tormey D.C. J. Clin. Oncol. 3 (1985) 311
14. Miller T.P., Grogan T.M., Dalton W.S., Spier C.M., Scheper R.J., and Salmon S.E. J. Clin. Oncol. 9 (1991) 17
15. Matin K., Egorin M.J., Ballesteros M.F., Smith D.C., Lembersky B., Day R.S., Johnson C.S., and Trump D.L. Cancer Chemother. Pharmacol. 50 (2002) 179
16. Lum B.L., Kaubisch S., Fisher G.A., Brown B.W., and Sikic B.I. Cancer Chemother. Pharmacol. 45 (2000) 305
17. Friedenberg W.R., Rue M., Blood E.A., Dalton W.S., Shustik C., Larson R.A., Sonneveld P., and Greipp P.R. Cancer 106 (2006) 830
18. Hyafil F., Vergely C., Du Vignaud P., and Grand-Perret T. Cancer Res. 53 (1993) 4595
19. Roe M., Folkes A., Ashworth P., Brumwell J., Chima L., Hunjan S., Pretswell I., Dangerfield W., Ryder H., and Charlton P. Bioorg. Med. Chem. Lett. 9 (1999) 595
20. Walker C., Martin, and Callaghan R. Eur. J. Cancer. 40 (2004) 594
21. Mistry P., Stewart A.J., Dangerfield W., Okiji S., Liddle C., Bootle D., Plumb J.A., Templeton D., and Charlton P. Cancer Res. 61 (2001) 749
22. Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M., Bumol T.F., and Starling J.J. Cancer Res. 56 (1996) 4171
23. Newman M.J., Rodarte J.C., Benbatoul K.D., Romano S.J., Zhang C., Uyeda R.T., Moran E.J., Dixon R., Guns E.S., and Mayer L.D. Cancer Res. 60 (2000) 2964
24. Pusztai L., Wagner P., Ibrahim N., Rivera E., Theriault R., Booser D., Symmans F.W., Wong F., Blumenschein G., Fleming D.R., Rouzier R., Boniface G., and Hortobagyi G.N. Cancer 104 (2005) 682
25. McMillian M.K., Li L., Parker J.B., Patel L., Zhong Z., Gunnett J.W., Powers W.J., and Johnson M.D. Cell Biol. Toxicol. 18 (2002) 157
26. Berger D., Citarella R., Dutia m., Greenberger L., Hallett W., Paul R., and Powell D. J. Med. Chem. 42 (1999) 2145
27. Singh S.S. Curr. Drug Metab. 7 (2006) 165
28. Peng F.C., Chang C.C., Yang C.Y., Edwards R.J., and Doehmer J. Toxicology 218 (2006) 172
29. Schellens J.H., Malingre M.M., Kruijtzer C.M., Bardelmeijer H.A., van Tellingen O., Schinkel A.H., and Beijnen J.H. Eur. J. Pharm. Sci. 12 (2000) 103
30. Kuppens I.E., Breedveld P., Beijnen J.H., and Schellens J.H. Cancer Invest. 23 (2005) 443
31. Gustafson D.L., Long M.E., Bradshaw E.L., Merz A.L., and Kerzic P.J. Cancer Chemother. Pharmacol. 56 (2005) 248
32. Walle U.K., and Walle T. Drug. Metab. Dispos. 26 (1998) 343
33. Sparreboom A., Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K.F., Borst P., Nooijen W.J., Beijnen J.H., and Tellingen O. Proc. Natl. Acad Sci. U.S.A. 94 (1997) 2031
34. Callies S., de Alwis D.P., Harris A., Vasey P., Beijnen J.H., Schellens J.H., Burgess M., and Aarons L. Br. J. Clin. Pharmacol. 56 (2003) 463
35. Dantzig A.H., Shepard R.L., Law K.L., Tabas L., Pratt S., Gillespie J.S., Binkley S.N., Kuhfeld M.T., Starling J.J., and Wrigh S.A. J. Pharmacol. Exp. Ther. 290 (1999) 854
36. Michael M., and Doherty M.M. J. Clin. Oncol. 23 (2005) 205
37. Houston J.B., and Galetin A. Arch. Biochem. Biophys. 433 (2005) 351